Alzheimer's Clinical Trials Consortium (ACTC)

阿尔茨海默病临床试验联盟 (ACTC)

• 批准号: 10435786
• 负责人: Paul S. Aisen
• 金额: $ 23.05万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-12-02 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10435786
• 关键词: Agreement; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Autopsy; Bioinformatics; Biological Assay; Biological Markers; Biometry; Blood; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Network; Cognitive; Collaborations; Combined Modality Therapy; Communities; Computer software; Contracts; Data; Data Analyses; Disease; Down Syndrome; Early intervention trials; Elderly; Enrollment; Fostering; Funding; Image; Individual; Informatics; Infrastructure; Institutes; Institutional Review Boards; Intervention; Leadership; Magnetic Resonance Imaging; Medical; Methods; Monitor; Network Infrastructure; Neurodegenerative Disorders; Outcome; Outcome Measure; Outcome Study; Participant; Pathology; Patient Recruitments; Phase; Play; Population; Population Heterogeneity; Positron-Emission Tomography; Prevention trial; Primary Prevention; Probability; Procedures; Protocols documentation; Readiness; Research; Research Design; Research Personnel; Resources; Risk; Role; Sampling; Secondary Prevention; Secure; Site; Specimen; Therapeutic; TimeLine; Tissues; United States National Institutes of Health; base; biobank; clinical care; cohort; cooperative study; data management; data sharing; design; drug development; effective therapy; electronic data capture system; eligible participant; experience; innovation; instrument; interest; meetings; mild cognitive impairment; neurodegenerative dementia; neuroimaging; neuropathology; next generation; novel; operation; participant retention; phenotypic data; polygenic risk score; pre-clinical; prediction algorithm; programs; public-private partnership; recruit; retention rate; tau Proteins; trial design

With this supplement, we request support to expand the NIH INCLUDE Trial-Ready Cohort-Down Syndrome (TRC-DS) project, which as part of the R61 phase (cohort) seeks to enroll 120 participants with DS, in advance of the R33 phase placebocontrolled clinical trial of an anti-amyloid therapeutic in this population. The specific aims of the TRC-DS project include building a readiness cohort that will both inform the design of a clinical trial as well as provide interested and eligible participants while collecting a rich set of participant-level phenotypic data. The Institute Jérôme Lejeune is a preeminent center in the world for clinical care of individuals with DS, including older adults with DS-related AD. Adding this site to the ACTC-DS network for participation in the TRC-DS project will further advance the impact and diversity of the project and establish a strong collaboration with an outstanding research team.

通过此补充，我们请求支持以扩展NIH INCLUDE Trial-Ready 队列唐氏综合征（TRC-DS）项目，作为R61阶段（队列）的一部分 旨在招募120名DS参与者，在该人群中进行抗淀粉样蛋白治疗的R33期安慰剂对照临床试验之前。具体 TRC-DS项目的目标包括建立一个准备队列， 临床试验的设计以及提供感兴趣和合格的参与者， 收集一组丰富的参与者水平的表型数据。Jérôme Lejeune学院 是一个卓越的中心，在世界上的临床护理个人与DS，包括 患有DS相关AD的老年人。将此站点添加到ACTC-DS网络， 参与TRC-DS项目将进一步推动 项目，并与优秀的研究团队建立强有力的合作。